This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kishi, S. Articles by Relling, M. V. Search for Related Content PubMed PubMed Citation Articles by Kishi, S. Articles by Relling, M. V. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB METHOTREXATE Social Bookmarking                            What's this?

Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia

Shinji Kishi, James Griener, Cheng Cheng, Soma Das, Edwin H. Cook, Deqing Pei, Melissa Hudson, Jeffrey Rubnitz, John T. Sandlund, Ching-Hon Pui, Mary V. Relling

From the Department of Pharmaceutical Sciences, Biostatistics, Hematology-Oncology, St. Jude Children’s Research Hospital, and University of Tennessee, Memphis, TN; Texas Tech School of Pharmacy, Amarillo, TX; and Department of Human Genetics, University of Chicago, Chicago, IL.

Address reprint requests to Mary V. Relling, PharmD, Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, 332 North Lauderdale, Memphis, TN 38105; email: mary.relling{at}stjude.org.

Purpose: Despite its clinical success, methotrexate (MTX) therapy is associated with toxicities such as seizures, the pathogenesis of which remains unclear. It has been suggested that hyperhomocysteinemia is caused by MTX and is responsible for its neurotoxic effects. The purposes of this study were to explore whether hyperhomocysteinemia was related to MTX administration and toxicity and whether homocysteine or MTX toxicity differed by methylenetetrahydrofolate reductase (MTHFR) or reduced folate carrier (RFC) genetic polymorphisms.

Patients and Methods: We studied 53 children with newly diagnosed acute lymphoblastic leukemia who were consecutively treated on a single clinical protocol that included two courses of high-dose MTX (high-dose methotrexate [HDMTX]; 2.5 or 5.0 g/m² per day) as consolidation therapy.

Results: The study participants’ median plasma homocysteine concentrations at 23 and 44 hours after HDMTX (9.00 µmol/L and 10.12 µmol/L, respectively) were greater than the concentrations immediately before HDMTX (5.77 µmol/L, P < .0001 for both comparisons). Seven days after HDMTX treatment, their plasma concentration returned to baseline. Nine patients experienced seizures, and five patients experienced thrombosis during the first 15 months of therapy, with a tendency for there to be higher plasma homocysteine in patients with seizures across all time points (P = .063) but not in patients with thrombosis (P = .59). We observed no significant differences in plasma or cerebrospinal fluid homocysteine levels or in toxicity based on the MTHFR 677C/T or RFC 80G/A genotypes.

Conclusion: We conclude that homocysteine was transiently elevated after HDMTX and may be related to seizure risk in children with leukemia.

Supported by grant nos. CA 51001, CA 78224, and CA21765 from the National Cancer Institute and the National Institutes of Health/National Institute of General Medical Sciences Pharmacogenetics Research Network and Database grant nos. U01GM61393 and U01GM61374 from the National Institutes of Health, Bethesda, MD; by a Center of Excellence grant from the State of Tennessee; and by American Lebanese Syrian Associated Charities. C-H.P. is an American Cancer Society F.M. Kirby Clinical Research Professor.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. E. Rubnitz, M. Onciu, S. Pounds, S. Shurtleff, X. Cao, S. C. Raimondi, F. G. Behm, D. Campana, B. I. Razzouk, R. C. Ribeiro, et al. Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital Blood, May 21, 2009; 113(21): 5083 - 5089. [Abstract] [Full Text] [PDF]

				C. G. Mullighan, X. Su, J. Zhang, I. Radtke, L. A.A. Phillips, C. B. Miller, J. Ma, W. Liu, C. Cheng, B. A. Schulman, et al. Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia N. Engl. J. Med., January 29, 2009; 360(5): 470 - 480. [Abstract] [Full Text] [PDF]

				D. French, L. H. Hamilton, L. A. Mattano Jr, H. N. Sather, M. Devidas, J. B. Nachman, and M. V. Relling A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group Blood, May 1, 2008; 111(9): 4496 - 4499. [Abstract] [Full Text] [PDF]

				S. Kishi, C. Cheng, D. French, D. Pei, S. Das, E. H. Cook, N. Hijiya, C. Rizzari, G. L. Rosner, T. Frudakis, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity Blood, May 15, 2007; 109(10): 4151 - 4157. [Abstract] [Full Text] [PDF]

				D. Gemmati, A. Ongaro, S. Tognazzo, L. Catozzi, F. Federici, E. Mauro, M. Della Porta, D. Campioni, A. Bardi, G. Gilli, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival Haematologica, April 1, 2007; 92(4): 478 - 485. [Abstract] [Full Text] [PDF]

				N. Hijiya, J. C. Panetta, Y. Zhou, E. P. Kyzer, S. C. Howard, S. Jeha, B. I. Razzouk, R. C. Ribeiro, J. E. Rubnitz, M. M. Hudson, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia Blood, December 15, 2006; 108(13): 3997 - 4002. [Abstract] [Full Text] [PDF]

				S. Jeha, F. Behm, D. Pei, J. T. Sandlund, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, N. Hijiya, S. C. Howard, C. Cheng, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia Blood, November 15, 2006; 108(10): 3302 - 3304. [Abstract] [Full Text] [PDF]

				J. Sterba, L. Dusek, R. Demlova, and D. Valik Pretreatment Plasma Folate Modulates the Pharmacodynamic Effect of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: "Folate Overrescue" Concept Revisited Clin. Chem., April 1, 2006; 52(4): 692 - 700. [Abstract] [Full Text] [PDF]

				C.-H. Pui, D. Pei, J. T. Sandlund, D. Campana, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, S. C. Howard, N. Hijiya, S. Jeha, et al. Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia J. Clin. Oncol., November 1, 2005; 23(31): 7936 - 7941. [Abstract] [Full Text] [PDF]

				W. E. Reddick, J. O. Glass, K. J. Helton, J. W. Langston, C.-S. Li, and C.-H. Pui A Quantitative MR Imaging Assessment of Leukoencephalopathy in Children Treated for Acute Lymphoblastic Leukemia without Irradiation AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2371 - 2377. [Abstract] [Full Text] [PDF]

				K. Robien Folate During Antifolate Chemotherapy: What We Know... and Do Not Know Nutr Clin Pract, August 1, 2005; 20(4): 411 - 422. [Abstract] [Full Text] [PDF]

				D. French, M. R. Wilkinson, W. Yang, L. de Chaisemartin, E. H. Cook, S. Das, M. J. Ratain, W. E. Evans, J. R. Downing, C.-H. Pui, et al. Global gene expression as a function of germline genetic variation Hum. Mol. Genet., June 15, 2005; 14(12): 1621 - 1629. [Abstract] [Full Text] [PDF]

				J. C. C. Rocha, C. Cheng, W. Liu, S. Kishi, S. Das, E. H. Cook, J. T. Sandlund, J. Rubnitz, R. Ribeiro, D. Campana, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia Blood, June 15, 2005; 105(12): 4752 - 4758. [Abstract] [Full Text] [PDF]

				R. Aplenc, J. Thompson, P. Han, M. La, H. Zhao, B. Lange, and T. Rebbeck Methylenetetrahydrofolate Reductase Polymorphisms and Therapy Response in Pediatric Acute Lymphoblastic Leukemia Cancer Res., March 15, 2005; 65(6): 2482 - 2487. [Abstract] [Full Text] [PDF]

				P. Brouwers Commentary: Study of the Neurobehavioral Consequences of Childhood Cancer: Entering the Genomic Era? J. Pediatr. Psychol., January 1, 2005; 30(1): 79 - 84. [Full Text] [PDF]

				M. V. Relling, W. Yang, S. Das, E. H. Cook, G. L. Rosner, M. Neel, S. Howard, R. Ribeiro, J. T. Sandlund, C.-H. Pui, et al. Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia J. Clin. Oncol., October 1, 2004; 22(19): 3930 - 3936. [Abstract] [Full Text] [PDF]

				W. L. Carroll, D. Bhojwani, D.-J. Min, E. Raetz, M. Relling, S. Davies, J. R. Downing, C. L. Willman, and J. C. Reed Pediatric Acute Lymphoblastic Leukemia Hematology, January 1, 2003; 2003(1): 102 - 131. [Abstract] [Full Text] [PDF]